Abivax stock drops more than 10% in a week ahead of its results
The Paris-based biotech closes the session in sharp decline, going against the grain of the SBF 120 which closes up. The stock is well below its three moving averages, just days before the publication of its half-yearly results, scheduled for September 21.
A decline that adds to already marked selling pressure over the past month
Abivax fell 3.62% to €90.45 at close, ranking among the largest declines of the SBF 120 in a session where the index nonetheless gained 0.65%. The decline is part of a trend that has been in place for several weeks: over one month, the stock lost nearly 12%, and over seven days, the decline exceeded 10%. The divergence from moving averages illustrates the extent of the pressure: the price is below the MA20 at €99.59 (gap of 9.18%), below the MA200 at €102.89 (gap of 12.09%) and below the MA50 at €108 (gap of 16.25%).
This configuration places the stock in a zone of clear technical weakness, contrary to the Paris market which closes in positive territory. It should be noted that the one-year performance remains positive at 26.15%, which testifies to the magnitude of the correction that has occurred since the highs reached earlier in the year.
Bearish positions on the rise ahead of half-yearly results next week
The RSI at 32 reflects a configuration close to oversold, without this level yet signaling clear selling exhaustion. This technical context overlaps with a rise in bearish positions: according to the declarations reviewed, five funds cumulate 5.77% of capital sold short, increasing by 0.73 percentage points over one month (compared to 5.04% thirty days ago). This elevated level testifies to a defensive institutional positioning on the value, without it being possible to identify the precise motivation. The analyst consensus on Abivax has not been updated in the available data. The next concrete milestone remains the publication of results for the first half of 2026, scheduled for September 21.
